Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Arqit Quantum Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Arqit Quantum Inc trades at $20.02 (market cap $345.44M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 13× Arqit Quantum Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ARQQ | |
|---|---|---|
Market Cap | $4.49B | $345.44M |
Sector | Health | Technology |
52-Week High | $28.06 | $58.27 |
52-Week Low | $20.06 | $11.78 |
Enterprise Value | $3.69B | $318.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ARQQ trades at $22.13, down 5.89% today, with a bullish technical signal supported by moving averages. The company reported $530K revenue for 2025 but significant losses of -$35.34M net income, with negative margins and high P/S ratio of 319.93. Recent news highlights quantum security contract wins and 829% YoY revenue growth in H1 FY26, suggesting potential turnaround momentum despite current financial challenges.
Outlook remains speculative with high execution risk; substantial revenue growth and government/telecom deals offer upside, but persistent losses and negative ROE (-181%) pose significant shareholder value concerns. Analyst consensus is divided with 50% buy rating, indicating cautious optimism amid financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
